Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Obstetrics & Gynecology, Amsterdam University Medical Center (UMC) Location, VU University Medical Center, Amsterdam, the Netherlands.
J Natl Cancer Inst. 2021 Jun 1;113(6):699-709. doi: 10.1093/jnci/djaa163.
Long-term effects of assisted reproductive technology (ART) on ovarian tumor risk are unknown.
This nationwide cohort study comprises 30 625 women who received ovarian stimulation for ART in 1983-2000 and 9988 subfertile women not treated with ART. Incident invasive and borderline ovarian tumors were ascertained through linkage with the Netherlands Cancer Registry and the Dutch Pathology Registry until July 2018. Ovarian tumor risk in ART-treated women was compared with risks in the general population and the subfertile non-ART group. Statistical tests were 2-sided.
After a median follow-up of 24 years, 158 invasive and 100 borderline ovarian tumors were observed. Ovarian cancer risk in the ART group was increased compared with the general population (standardized incidence ratio [SIR] = 1.43, 95% confidence interval [CI] = 1.18 to 1.71) but not when compared with the non-ART group (age- and parity-adjusted hazard ratio [HR] = 1.02, 95% CI = 0.70 to 1.50). Risk decreased with higher parity and with a larger number of successful ART cycles (resulting in childbirth, Ptrend = .001) but was not associated with the number of unsuccessful ART cycles. Borderline ovarian tumor risk was increased in ART-treated women compared with the general population (SIR = 2.20, 95% CI = 1.66 to 2.86) and with non-ART women (HR = 1.84, 95% CI = 1.08 to 3.14). Risk did not increase with more ART cycles or longer follow-up time.
Increased ovarian cancer risk in ART-treated women compared with the general population is likely explained by nulliparity rather than ART treatment. The increased risk of borderline ovarian tumors after ART must be interpreted with caution because no dose-response relationship was observed.
辅助生殖技术(ART)对卵巢肿瘤风险的长期影响尚不清楚。
这项全国性队列研究纳入了 1983 年至 2000 年间接受卵巢刺激以进行 ART 的 30625 名女性和 9988 名未接受 ART 治疗的不孕女性。通过与荷兰癌症登记处和荷兰病理登记处的链接,确定了侵袭性和交界性卵巢肿瘤的发病情况,直至 2018 年 7 月。与一般人群和未接受 ART 的不孕不育非 ART 组相比,ART 治疗女性的卵巢肿瘤风险。统计检验为双侧。
中位随访 24 年后,观察到 158 例侵袭性和 100 例交界性卵巢肿瘤。与一般人群相比,ART 组的卵巢癌风险增加(标准化发病比 [SIR] = 1.43,95%置信区间 [CI] = 1.18 至 1.71),但与非 ART 组相比无差异(年龄和产次调整后的风险比 [HR] = 1.02,95%CI = 0.70 至 1.50)。风险随较高的产次和较多的成功 ART 周期(导致分娩,Ptrend =.001)而降低,但与不成功的 ART 周期数量无关。与一般人群相比,ART 治疗女性的交界性卵巢肿瘤风险增加(SIR = 2.20,95%CI = 1.66 至 2.86),与非 ART 女性相比(HR = 1.84,95%CI = 1.08 至 3.14)。风险并未随更多的 ART 周期或更长的随访时间而增加。
与一般人群相比,ART 治疗女性的卵巢癌风险增加可能是由于未育而非 ART 治疗所致。ART 后交界性卵巢肿瘤风险增加必须谨慎解释,因为未观察到剂量-反应关系。